These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 32264785)

  • 21. Hypothyroidism in Cancer Patients on Immune Checkpoint Inhibitors with anti-PD1 Agents: Insights on Underlying Mechanisms.
    Alhusseini M; Samantray J
    Exp Clin Endocrinol Diabetes; 2017 Apr; 125(4):267-269. PubMed ID: 28073132
    [No Abstract]   [Full Text] [Related]  

  • 22. Multiple autoimmune side effects of immune checkpoint inhibitors in a patient with metastatic melanoma receiving pembrolizumab.
    Kethireddy N; Thomas S; Bindal P; Shukla P; Hegde U
    J Oncol Pharm Pract; 2021 Jan; 27(1):207-211. PubMed ID: 32390537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events.
    Mihic-Probst D; Reinehr M; Dettwiler S; Kolm I; Britschgi C; Kudura K; Maggio EM; Lenggenhager D; Rushing EJ
    Immunobiology; 2020 Sep; 225(5):152009. PubMed ID: 32962812
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Thyroid disorders in programmed death 1 inhibitor-treated patients: Is previous therapy with tyrosine kinase inhibitors a predisposing factor?
    Sbardella E; Tenuta M; Sirgiovanni G; Gianfrilli D; Pozza C; Venneri MA; Cortesi E; Marchetti P; Lenzi A; Gelibter AJ; Isidori AM
    Clin Endocrinol (Oxf); 2020 Mar; 92(3):258-265. PubMed ID: 31788837
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Permanent hypothyroidism following immune checkpoint inhibitors induced thyroiditis may be associated with improved survival: results of an exploratory study.
    Lee HJ; Manavalan A; Stefan-Lifshitz M; Schechter C; Maity A; Tomer Y
    Front Endocrinol (Lausanne); 2023; 14():1169173. PubMed ID: 37168978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BASELINE TSH LEVEL IS ASSOCIATED WITH RISK OF ANTI-PD-1-INDUCED THYROID DYSFUNCTION.
    Pollack RM; Kagan M; Lotem M; Dresner-Pollak R
    Endocr Pract; 2019 Aug; 25(8):824-829. PubMed ID: 31013164
    [No Abstract]   [Full Text] [Related]  

  • 28. Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: a long-term prospective study from a referral institution.
    Guaraldi F; La Selva R; Samà MT; D'Angelo V; Gori D; Fava P; Fierro MT; Savoia P; Arvat E
    J Endocrinol Invest; 2018 May; 41(5):549-556. PubMed ID: 29043574
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ophthalmic Immune-Related Adverse Events after Anti-CTLA-4 or PD-1 Therapy Recorded in the American Academy of Ophthalmology Intelligent Research in Sight Registry.
    Sun MM; Kelly SP; Mylavarapu Bs AL; Holland GN; Coleman AL; Yu F; Hsu Ms S; Lum F; Gordon LK
    Ophthalmology; 2021 Jun; 128(6):910-919. PubMed ID: 33166553
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Endocrine Adverse Events Caused by Different Types and Different Doses of Immune Checkpoint Inhibitors in the Treatment of Solid Tumors: A Meta-Analysis and Systematic Review.
    Yang Y; Liu J; Yang K; Ma Y; Fu S; Tang X; Wang Y; Zhou L
    J Clin Pharmacol; 2021 Mar; 61(3):282-297. PubMed ID: 33345342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Incidence of thyroid dysfunction caused by immune checkpoint inhibitors combined with chemotherapy: A systematic review and meta-analysis.
    Yang P; Shen G; Zhang H; Zhang C; Li J; Zhao F; Li Z; Liu Z; Wang M; Zhao J; Zhao Y
    Int Immunopharmacol; 2024 May; 133():111961. PubMed ID: 38608442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H; Nakagawa K
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune checkpoint inhibitor-associated thyroid dysfunction: a disproportionality analysis using the WHO Adverse Drug Reaction Database, VigiBase.
    Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Lin X
    Eur J Endocrinol; 2020 Jan; 182(1):1-9. PubMed ID: 31648184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors.
    Lima Ferreira J; Costa C; Marques B; Castro S; Victor M; Oliveira J; Santos AP; Sampaio IL; Duarte H; Marques AP; Torres I
    Cancer Immunol Immunother; 2021 Feb; 70(2):299-309. PubMed ID: 32712715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors.
    König D; Läubli H
    Pharmacology; 2021; 106(3-4):123-136. PubMed ID: 32721966
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune Checkpoint Inhibitors-Related Thyroid Dysfunction: Epidemiology, Clinical Presentation, Possible Pathogenesis, and Management.
    Zhan L; Feng HF; Liu HQ; Guo LT; Chen C; Yao XL; Sun SR
    Front Endocrinol (Lausanne); 2021; 12():649863. PubMed ID: 34177799
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immune-Checkpoint Inhibitors-Induced Type 1 Diabetes Mellitus: From Its Molecular Mechanisms to Clinical Practice.
    Cho YK; Jung CH
    Diabetes Metab J; 2023 Nov; 47(6):757-766. PubMed ID: 37482654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells.
    Anderson R; Theron AJ; Rapoport BL
    Front Immunol; 2019; 10():2254. PubMed ID: 31616428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune checkpoint inhibitors and endocrine side effects, a narrative review.
    Agrawal L; Bacal A; Jain S; Singh V; Emanuele N; Emanuele M; Meah F
    Postgrad Med; 2020 Mar; 132(2):206-214. PubMed ID: 31876444
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions.
    Atkins MB; Clark JI; Quinn DI
    Ann Oncol; 2017 Jul; 28(7):1484-1494. PubMed ID: 28383639
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.